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Abstract
Background
To our knowledge, no publication providing overarching guidance on the conduct of system-
atic reviews of observational studies of etiology exists.
Methods and findings
Conducting Systematic Reviews and Meta-Analyses of Observational Studies of Etiology
(COSMOS-E) provides guidance on all steps in systematic reviews of observational studies
of etiology, from shaping the research question, defining exposure and outcomes, to
assessing the risk of bias and statistical analysis. The writing group included researchers
experienced in meta-analyses and observational studies of etiology. Standard peer-review
was performed. While the structure of systematic reviews of observational studies on etiol-
ogy may be similar to that for systematic reviews of randomised controlled trials, there are
specific tasks within each component that differ. Examples include assessment for con-
founding, selection bias, and information bias. In systematic reviews of observational stud-
ies of etiology, combining studies in meta-analysis may lead to more precise estimates, but
such greater precision does not automatically remedy potential bias. Thorough exploration
of sources of heterogeneity is key when assessing the validity of estimates and causality.
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Conclusion
As many reviews of observational studies on etiology are being performed, this document
may provide researchers with guidance on how to conduct and analyse such reviews.
Introduction
Systematic reviews aim to appraise and synthesise the available evidence addressing a specific
research question; a meta-analysis is a statistical summary of the results from relevant studies.
A systematic review should generally be the basis of a meta-analysis, whereas a meta-analysis is
not a necessary feature of a systematic review if reviewers decide that pooling of effect esti-
mates is not appropriate. Many systematic reviews are based on observational studies. In 2014,
of about 8,000 systematic reviews published that year, 36% were on etiology, prognosis, or
diagnosis [1].
Etiological studies examine the association of exposures with diseases or health-related out-
comes. Exposures potentially causing diseases are also called risk factors and may take many
forms; they can be fixed states (e.g., sex, genetic factors) or vary over time, for example meta-
bolic risk factors (e.g., hypercholesterolemia, insulin resistance, hypertension), lifestyle habits
(e.g., smoking, diet), or environmental factors (e.g., air pollution, heat waves). Conceptually,
these exposures differ from interventions, which explicitly aim to influence health outcomes
and have a clear starting point in time [2]. Observational studies are important to study expo-
sures that are difficult or impossible to study in randomised controlled trials (RCTs), such as
air pollution or smoking. Also, observational studies are important to study causes with long
latency time, such as carcinogenic effects of environmental exposures or drugs.
The epidemiological study of risk factors typically relies on comparisons (exposed versus
unexposed); such comparisons can be made in cohort studies in which exposed and unexposed
people are followed over time [3]. Other approaches such as self-controlled studies, case-con-
trol studies, cross-sectional studies, ecological studies, instrumental variable analyses, and
mendelian randomisation also rely on comparisons. Box 1 presents an overview of observa-
tional study designs used to study etiology.
Aim and scope of COSMOS-E
For systematic reviews of randomised trials, guidelines on conduct [14] and reporting [15]
have been widely adopted. For systematic reviews of observational studies, reporting guide-
lines were published almost two decades ago [16], and, to date, there are, to our knowledge, no
guidelines on their conduct. Despite similarities in the general structure of the review, the
‘roadmap’ of systematic reviews of observational studies is less standardised [17], and some
design issues are not settled yet [18]. The aim of Conducting Systematic Reviews and Meta-
Analyses of Observational Studies of Etiology (COSMOS-E) is to discuss and give guidance on
key issues in systematic reviews of observational studies of etiology for researchers. We address
all steps in a review on observational studies, even though some will be similar to reviews of
RCTs of medical interventions. COSMOS-E covers the basic principles as well as some more
advanced topics but does not address systematic reviews of nonrandomised studies of inter-
ventions, or of diagnostic, prognostic, or genetic studies. COSMOS-E is not formally meant to
be a guideline; it provides guidance but does not formally prescribe how researchers should
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Box 1. Observational designs and approaches for studying etiology
Cohort study
Cohort studies follow a study population over time. Researchers can study the occur-
rence of different outcomes. In etiological research, an exposed and an unexposed group
are compared regarding the risk of the outcome. Different levels of exposure and expo-
sures that vary over time can be studied. Instrumental variable methods and self-con-
trolled case series studies are types of cohort studies (see below).
Example
In a large population-based cohort study, the occurrence of infectious complications was
compared between patients with and patients without Cushing disease [4].
Instrumental variable methods/mendelian randomisation
Instrumental variable (IV) analyses use an external factor that determines the exposure
of interest but is (ideally) not associated with the outcome other than through its effect
on the exposure. In other words, the instrument is not associated with the factors that
may confound the association between exposure and outcome. The instrument can be
calendar time, geographical area, or treatment preferences [5,6]. Mendelian randomisa-
tion studies are examples of IV analyses using genetic factors as instruments.
Example
A Mendelian randomisation study investigated whether more years spent in education
increase the risk of myopia or whether myopia leads to more years spent in education
[7].
Self-controlled designs
In self-controlled case series, the occurrence of the outcome is compared between time
windows during which individuals are exposed to a risk factor and time windows not
exposed. In contrast to standard cohort designs, the comparison is within individuals.
The design is used to study transient exposures for which exact timings are available,
such as infections, vaccinations, drug treatments, climatic exposures, or disease exacer-
bations [8].
Example
A self-controlled study examined the effect of cold spells and heat waves on admissions
for coronary heart disease, stroke, or heart failure in Catalonia [9].
Case-control study
In case-control studies, exposures are compared between people with the outcome of
interest (cases) and people without (controls) [3]. The design is especially efficient for
rare outcomes.
Example
A multicentre case-control study examined the association between mobile phone use
and primary central nervous system tumours (gliomas and meningiomas) in adults [10].
Cross-sectional studies
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perform or report their review. Also, this paper will not settle some ongoing debates and con-
troversies [18] around the performance of reviews of observational studies on etiology, but
rather will give the different viewpoints and possibilities. The writing group included research-
ers experienced in meta-analyses and observational studies of etiology. No external advise was
sought; standard peer-review was performed.
Preparing the systematic review
Building a review team
At the design stage, the team should cover both content knowledge and methodological exper-
tise. For example, identifying potential confounding variables or assessing exposure measure-
ments requires content knowledge. Similarly, the statistical analysis can often be complex,
highlighting the need for statistical expertise. Questions may arise about whether and how dif-
ferent designs (for example, case-control studies and cohort studies) can be combined in
meta-analysis or whether a dose-response meta-analysis is feasible. An information specialist
will ensure comprehensive and efficient literature searches.
Shaping the research question
A systematic review of observational studies requires a clear research question, which can be
broad initially but should be narrowed down subsequently in the interest of clarity and feasibil-
ity. In other words, and contrasting with systematic reviews for RCTs, the research question
In cross-sectional studies, study participants are assessed at the same point in time to
examine the prevalence of exposures, risk factors, or disease. The prevalence of disease is
then compared between exposure groups like in a cohort study, or the odds of exposure
are compared between groups with and without disease, like in a case-control study [3].
The temporal relationship between exposure and outcome can often not be determined
in cross-sectional studies.
Example
A cross-sectional analysis of the United Kingdom Biobank study examined whether
neighbourhood exposure to fast-food outlets and physical activity facilities was associ-
ated with adiposity [11].
Ecological studies
In ecological studies, the association between an exposure and an outcome is studied
and compared between populations that differ geographically or in calendar time. Limi-
tations include the ecological fallacy, in which associations observed at the aggregate
level do not hold at the individual level and confounding, which is often difficult to
control.
Example
An ecological study of male circumcision practices in different regions of sub-Saharan
Africa and HIV infection found that HIV prevalence was lower in areas where male cir-
cumcision was practiced than in areas where it was not [12]. The protective effect of
male circumcision was later confirmed in randomised trials [13].
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may be iterative. After framing the question, reviewers should scope key papers to get an idea
of what evidence is available about the problem, including what type of research has been
done. This exploratory step has two aims. It clarifies whether the question has already been
addressed in a recent systematic review and indicates whether and how the question needs to
be refined and focused so that it can be the subject of feasible systematic review.
Defining population, exposure, contrast, and outcome
In line with the well-known Population, Intervention, Control, and Outcome(s) (PICO) for-
mat [15], for systematic reviews of epidemiological studies, Population, Exposure, Control,
and Outcome(s) (PECO) should be defined [19]. The study population should reflect the target
population, i.e., the population to which the results should be applicable [20]. This can be the
general population, as in a meta-analysis of the association of insulin-like growth factor and
mortality [21], or a restricted population, such as in a review of the association between breast-
feeding and childhood leukemia [22]. The study population must be defined such that the
exposure–outcome association can be validly studied [23]. For example, if a radiation exposure
is assumed to damage growing tissues, then children are a more appropriate study population
than adults (see discussion of ‘study sensitivity’ [23] later in this article).
Studies on risk factors should ideally include people who are free of the outcome under
study at start of follow-up, but this is often unverifiable in population-based studies. Subclini-
cal or early disease might go undetected if such conditions are not ruled out explicitly. In a
review on the association between insulin resistance and cardiovascular events, not all popula-
tion-based studies explicitly excluded participants with cardiovascular disease at baseline.
These studies were not excluded but considered at higher risk of bias [24].
Exposure(s) and outcome(s) should be clearly defined. The definition and measurement of
many exposures in observational studies of etiology, such as socioeconomic status, diet, exer-
cise, or environmental chemicals, need careful attention, and the comparability of assessments
across studies needs to be assessed. Similarly, many outcomes—such as diseases (e.g., breast
cancer, thrombosis, diabetes mellitus) or health-related states (e.g., quality of life, levels of risk
factors)—can be defined, classified, or measured in many different ways. Consideration of out-
comes thus includes not only ‘what’ is the outcome of interest but also ‘how’ it was determined.
Only death is insensitive to method of measurement or ascertainment. The exposure–control
comparison also needs attention. In a study of the effect of leisure physical activity, the expo-
sure category (for example, weekly sport for more than 2 hours) might be compared to either
less than 2 hours per week or to no sport. Neither of these comparisons is wrong, but they
address different questions.
Reviewers may develop precise definitions and criteria for exposure and outcomes, but if
no single study used these definitions, the review will not be able to answer the research
question. Iteration and pragmatism are required in this situation. In the case of fat mass and
cardiovascular risk, a sophisticated exposure measurement—magnetic resonance imaging
(MRI)—may have been used only in a few small studies. The reviewers may then decide also
to include studies using body mass index or waist:hip ratio, which will ensure the inclusion
of more and larger studies. Whether the studies can be combined statistically in a meta-
analysis is a different question, which we will address later in this article.
Considering confounding and bias
Confounding is a crucial threat to the validity of observational studies. Confounding occurs
when comparison groups differ with respect to their risk of the outcome beyond the exposure
(s) of interest due to a common cause of exposure and outcome. When planning the review,
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researchers should carefully consider which factors might potentially confound the exposure–
outcome associations under study. Importantly, confounding is not a yes/no phenomenon but
a matter of degree. For example, strong confounding is expected in studies that compare mor-
tality between vegetarians and nonvegetarians because these groups will differ in many other
lifestyle characteristics, which will be associated with causes of death. The opposite is true
when studying smoking as a cause of lung cancer. There will be little confounding because
other strong risk factors for lung cancer are rare, and it is also unlikely that they are strongly
associated with smoking. In general, strong confounding is unlikely for adverse effects that
were unexpected at the time the study was conducted, for example, the link between asbestos
and mesothelioma [25]. Indeed, substantial confounding may be rare in occupational epidemi-
ology, even by risk factors strongly associated with the outcome of interest [26].
Other threads to the validity of the effect estimation are measurement (misclassification)
bias or selection bias. Misclassification is a crucial bias in environmental and occupational epi-
demiology, particularly for long-term exposures [26]. Thinking up front about potential con-
founding and bias will facilitate the ‘scoping’ of the crucial validity threats for the specific
research question and judgments on what types of studies are likely to provide the most unbi-
ased estimate.
The protocol
Every systematic review should be planned in a detailed protocol. The key issues that need to
be addressed are listed in Box 2. It is not always possible to specify fully all review methods
beforehand; the writing of the study protocol will often be an iterative process, informed by
scoping the literature and piloting procedures. Reviewers should take care not to change the
protocol based on study results, but the protocol may be adapted, for example, based on the
Box 2. Key elements of a protocol for a systematic review of
observational studies of etiology
1. Background and rationale
2. Review question(s)
3. Definition of exposures, contrasts, and outcomes
4. Tabulation of potential confounders and biases that could affect study results
5. Study eligibility criteria
6. Literature search for relevant studies
7. Data extraction (study characteristics and results)
8. Assessment of risk of bias and study sensitivity
9. Statistical methods
10. Planned analyses
11. Approach to how the body of evidence will be judged
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number and type of available studies. Registering the protocol in the International Prospective
Register of Systematic Reviews (PROSPERO) [27] increases transparency and allows editors,
peer reviewers, and others to compare planned methods with the published report and to iden-
tify inconsistencies or selective reporting of results. This does not mean that protocol devia-
tions are not possible, but such changes or additions should be made transparent in the
reporting phase.
Searching for relevant studies
Searching for eligible studies is a process that includes several steps: (i) selection of electronic
databases to be searched (e.g., MEDLINE, EMBASE, specialised databases such as Toxicology
Literature Online [Toxline], or databases of regulatory authorities); (ii) developing of search
strategies and piloting and refining these in collaboration with an information scientist or
librarian [28]; (iii) consideration of other approaches, such as citation tracking or scrutinising
references of key papers; and (iv) deciding whether to search the grey literature (e.g., confer-
ence abstracts, theses, preprints). As many relevant studies may be identified in sources other
than electronic databases [29,30], searches that extend beyond the standard electronic data-
bases should be considered.
Identification of observational study designs in literature databases is not straightforward,
as the indexing of study types can be inaccurate. Several electronic databases should be
searched, as no single database has adequate coverage of all the relevant literature [31]. A bib-
liographic study concluded that no efficient systematic search strategies exist to identify epide-
miologic studies [32]. Compiling a list of key studies that should be identified is helpful to
check the sensitivity of the electronic search strategy. As the number of hits from the search
may be very large relative to the number of eligible studies, the challenge is to focus the search
as much as possible without compromising sensitivity. Summarized Research in Information
Retrieval for Human Technology Assessment (HTA) (www.sure–info.org) is a web-based
resource that provides guidance on sources to search and on designing search strategies,
including search filters to identify observational studies. The incremental value of searching
for observational studies in languages other than English has not been evaluated but will
depend on the research question. In general, it is prudent to assume that language restrictions
could introduce bias. Researchers should search not only for studies on ‘the exposure and out-
come’ of interest but have an open mind for studies with negative exposure and outcome con-
trols, ecological and time trend studies of exposure and/or outcome, and papers from basic
science.
Study selection
The search produces bibliographic references with information on authors, titles, journals, etc.
However, the unit of interest is the study and not the publication—the same study might have
been reported more than once [33], and a single publication can report on multiple studies.
First, all identified reports are screened based on title and abstract to remove duplicate publica-
tions and articles that are clearly not relevant. This leads to a set of studies for which the full
texts are required to determine eligibility and potential overlaps in study populations. Even
with clearly defined eligibility criteria, not all decisions will be straightforward. For example, if
researchers want to perform a review restricted to children, some studies may have included
young adults without providing data for children only. In this case, reviewers may have to
decide what proportion of adults is acceptable for a study to be included, or they may attempt
to obtain the data on children from the authors.
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There is no standard answer to the question of whether study design or methodological
quality should guide inclusion of studies [18]. If, for a specific review, a design characteristic is
clearly related to high risk of bias and easy to identify (for example, case-control studies of
long-term exposures), then such studies could be excluded upfront. An argument for not
restricting reviews in this way is that the assessment of risk of bias will often be subjective to
some extent, potentially leading to inappropriate exclusions of studies, and that including all
studies may lead to important insights when exploring between-study heterogeneity [34].
Recording and reporting reasons for exclusions enhances the transparency of the process
and informs sensitivity analyses to examine the effect of excluding or including studies.
Reviewers should therefore document their decisions throughout the process of study selection
and summarise it in a flowchart. Fig 1 gives an example. Dedicated software to support the
process of selecting studies may be helpful (see http://systematicreviewtools.com/), including
tools using machine learning and text mining to partially automate finding eligible studies and
extracting data from articles.
Data extraction
Article screening, data extraction, and assessments of risk of bias should preferably be done
independently by two reviewers to reduce errors and to detect any differences in interpretation
between extractors [35,36]. Discrepancies can then be discussed and resolved [37]. Standard-
ised data extraction sheets should be developed for each review, piloted with a few typical stud-
ies, refined, and then implemented in generic (for example, EpiData) or preferably dedicated
software (for example, Covidence; see http://systematicreviewtools.com). For all included
studies, the following core data should be extracted:
1. Bibliographic information
2. Study design
3. Risk of bias assessment
4. Exposure(s) and outcomes, including definitions
5. Characteristics of study participants
Fig 1. Flow chart of study selection. From [15].
https://doi.org/10.1371/journal.pmed.1002742.g001
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6. Numerical results: number of participants per group, number with outcome
7. Effect estimates (adjusted and unadjusted) and their standard errors
Bibliographic information includes the journal or preprint server, publication year, volume
and page numbers, and digital object identifier (doi). The definition of the study design should
be based on an assessment of what was done, not on how the study was described in the title or
indexed in a database [3]. Indexing of observational study designs is often inadequate, and
authors may themselves confuse designs. In specialty journals, 30%–50% of studies indexed as
’case-control studies’ are not in fact case-control studies [38,39]. Characteristics of study par-
ticipants and outcomes are extracted separately for exposed and unexposed (cohort studies) or
cases and controls (case-control studies).
Extracting effect estimates and standard errors
Studies will typically report an effect estimate and a measure of precision (confidence interval)
or P value. The effect estimates may be odds ratios, rate ratios, risk ratios, or risk differences
for studies with a dichotomous outcome and the difference in means for continuous outcomes.
In general, extraction of the standard error or standard deviation may not be straightforward
(a standard error may wrongly be described as standard deviation or vice versa), and some-
times, the standard error needs to be calculated indirectly. S1 Box provides practical guidance.
The confounder-adjusted estimates will be of greatest interest for observational studies, but
it is useful to additionally extract the unadjusted estimates or raw data. Comparisons of
adjusted and crude estimates allow insights into the importance of confounding. Many studies
Fig 2. The causal structures of confounding and selection bias.
https://doi.org/10.1371/journal.pmed.1002742.g002
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report effect estimates from different models, adjusted for different sets of confounders. In this
situation, meta-analyses of maximally adjusted estimates and minimally adjusted or crude esti-
mates may be performed, as was done in a meta-analysis of insulin-like growth factor and can-
cer risk [40].
Assessing quality and bias
The assessment of methodological aspects of studies is a crucial component of any systematic
review. Observational studies may yield estimates of associations that deviate from true under-
lying relationships due to confounding or biases. Meta-analyses of observational studies may
therefore produce ‘very precise but equally spurious’ results [41].
The term ‘study quality’ is often used in this context, but it is important to distinguish
between quality and risk of bias. The quality of a study will be high if the authors have per-
formed the best possible study. However, a high-quality study may still be at high risk of bias.
For example, in a case-control study of lifetime alcohol consumption and endometrial cancer
risk, the authors used a state-of-the art population-based design to reduce the risk of selection
bias [42] but had to rely on self-reported alcohol intake over a lifetime. It is likely that some
women will have underreported their alcohol intake, introducing social desirability bias [43].
The concept of ‘study sensitivity’ [23] refers to the ability of studies to detect a true effect
and is more closely related to study quality than bias. If the study is negative, does this really
mean that there is evidence for no exposure–outcome association? For example, were the
numbers of exposed persons sufficient and the levels and duration of exposure adequate to
detect an effect? [23]. Was follow-up long enough to allow for the development of the cancer
of interest? Study sensitivity is particularly relevant in occupational and environmental epide-
miology but is also of great concern in pharmacoepidemiology in the context of adverse effects
of drugs. Reviewers should consider assessing both the risk of bias and study sensitivity in
reviews of observational studies.
Risk of bias in individual studies: Confounding, selection bias, and
information bias
Many possible sources of bias exist, and different terms are used to describe them. Bias typi-
cally arises either from flawed collection of information or selection of participants into the
study so that an association is found that deviates from the true value. Typically, bias is intro-
duced during the design or implementation of a study and cannot be remedied later.
In contrast to bias, confounding produces associations that are real but not causal because
some other, unaccounted factor is associated with both exposure and outcome (Box 3). Time-
dependent confounding is a special case of confounding (S2 Box). Confounding can be
adjusted for in the analysis if the relevant confounding variables have been well measured, but
some residual confounding may remain after adjustment (Box 4). Confounding is often con-
fused with selection bias. In particular, the situation in which comparison groups differ with
respect to an important prognostic variable is often described as selection bias. The term selec-
tion bias should, however, be used only for the situation in which participants, their follow-up
time, or outcome events are selected into a study or analysis in a way that leads to a biased
association between exposure and outcome. Directed acyclic graphs (DAGs) are useful to clar-
ify the structures of confounding and selection bias (see Box 3) [44]. Another important cate-
gory of bias is information bias, in which systematic differences in the accuracy of exposure or
outcome data may lead to differential misclassification of individuals regarding exposures or
outcomes. Bias needs to be distinguished from random error, a deviation from a true value
caused by chance variation in the data. Finally, it is important to note that confounding and
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selection bias refer to biases that are internal to the study (‘internal validity’) and not to issues
of generalisability or applicability (‘external validity’) [20]. How should the risk of bias in
observational studies best be assessed? A review identified more than 80 tools for assessing risk
of bias in nonrandomised studies [45]. The reviewers concluded that there is no ‘single obvious
candidate tool for assessing quality of observational epidemiological studies’. This is not sur-
prising considering the large heterogeneity in study designs, contexts, and research questions
in observational research. We believe that the quest for a ‘one size fits all’ approach is mis-
guided; rather, a set of criteria should be developed for each observational systematic review
and meta-analysis, guided by the general principles outlined below.
General principles
When assessing the risk of bias, seven general principles are relevant, based on theoretical con-
siderations, empirical work, and the experience with assessing risk of bias in RCTs and other
studies [55–57].
1. The relevant domains of bias should be defined separately for each review question
and for different study designs. Relevant domains of risk of bias that should be considered
include (i) bias due to (time-dependent) confounding, (ii) bias in selection of participants into
the study (selection bias), (iii) bias in measurement of exposures or outcomes (information
bias), (iv) bias due to missing data (selection bias), and (v) bias in selection of studies or
reported outcomes (selection bias) [56]. The risk of bias should be assessed for each domain
and, if required, for different outcomes. The focus should be on bias. For example, whether or
not a sample size calculation was performed or ethical approval was obtained does not affect
the risk of bias.
Box 3. The causal structures of confounding and selection bias
A directed acyclic graph (DAG) consists of (measured and unmeasured) variables and
arrows. They are useful to depict causal structures: arrows are interpreted as causal
effects of one variable on another [37]. Common causes of exposure and outcome con-
found the association between exposure and outcome. For example, as shown in the
DAG in Fig 2, the association between yellow fingers and lung cancer is confounded by
smoking. The association is spurious, i.e., it is entirely explained by smoking.
Selection bias occurs if the probability of inclusion into the study depends both on the
exposure and the outcome. In a hospital-based case-control study, inclusion into the
study naturally depends on being admitted to the hospital; it is conditional on hospitali-
sation. For example, in a case-control study of alcohol and prostate cancer, the inclusion
of controls hospitalised because of injuries suffered in traffic accidents will introduce an
association between alcohol consumption and prostate cancer because alcohol is a cause
of traffic accidents (Fig 2 for a graphical display). In general, conditioning on common
effects of exposure and outcome means that the probability of inclusion depends on the
exposure and outcome, which leads to selection bias. This structure applies to many
biases, including nonresponse bias, missing data bias, volunteer bias or health worker
bias, or bias due to loss of follow-up in cohort studies [44]. All of these biases have the
causal structure of selection bias.
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Box 4. Approaches to deal with confounding in observational
studies
Statistical adjustment in the analysis
Statistical adjustment for confounding can be performed using standard regression tech-
niques (for example, Cox or logistic regression). All of these models, including more
advanced techniques such as propensity scores [46] or inverse probability weighting,
rely on the assumption of no unmeasured confounding for the validity of the effect esti-
mate. This assumption is often unlikely to hold in practice because some confounding
factors may not have been assessed or have not been measured precisely. Residual con-
founding may therefore persist after adjustment, which should be taken into account
when interpreting combined estimates from meta-analysis of observational studies.
Matching
Matching is an intuitive approach to control for confounding at the design stage of a
study, particularly in case-control research [47]. The choice of the variables, exact
approach to matching, and the statistical analysis are complex and need careful consider-
ation. Bias may be introduced, for example, when matching for variables that are on the
causal pathway from exposure to disease [3]. Matching is particularly relevant in situa-
tions in which the distribution of important confounders differs substantially between
cases and unmatched controls [48].
Instrumental variable methods
Instrumental variables may be useful to control for confounding [49]. An instrument is
an external variable that is associated with the exposure of interest but ideally is not asso-
ciated with the outcome variable other than through its effect on the exposure. In
essence, instrumental variables circumvent the problem of unmeasured confounding.
For example, mendelian randomisation studies make use of common genetic polymor-
phisms (for example, the rs1229984 variant in the alcohol dehydrogenase 1B gene) that
influence levels of modifiable exposures (alcohol intake [50]). As with any other instru-
mental variable analysis, the validity of mendelian randomisation depends critically on
the absence of a relationship between the instrument (genes) and the outcome (for
example, cardiovascular disease) [5].
Negative controls
The use of ‘negative controls’ for outcomes or exposures can be helpful to assess the
likely presence of unmeasured or residual confounding in observational research [51].
The rationale is to examine an association that cannot plausibly be produced by the
hypothesised causal mechanism but may be generated by the same sources of bias or
confounding as the association of interest. For example, it has been hypothesised that
smoking increases the risk of depression and suicide because of effects on serotonin and
monoamine oxidase levels [52]. However, in large cohort studies, smoking is also posi-
tively associated with the risk of being murdered—the negative, biologically implausible
outcome control [53]. Similarly, in cohort studies, vaccination against influenza not only
protected against hospitalisation for pneumonia but also against hospitalisation for
injury or trauma [46], indicating that the beneficial effect on pneumonia may have been
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2. The risk of bias should be assessed qualitatively. For each study and bias domain, the
risk of bias should be assessed in qualitative categories, for example, as ‘low risk’, ‘moderate
risk’, or ‘high risk’. These categories and the criteria used to define them should be described
in the paper. Quantitative assessments by assigning points should be avoided (see also point
6).
3. Signalling questions may be useful. Within each bias domain, simple signalling ques-
tions may be useful to facilitate judgments about the risk of bias (Table 1). A comprehensive
list of signalling questions has recently been compiled by the developers of the Cochrane risk
of bias assessment tool for nonrandomised studies of interventions (ROBINS-I) [56], and a
similar tool is in development for nonrandomised studies of exposures [58]. These lists and
tools will be useful, but reviewers should think about further questions that may be relevant in
the context of their review. Cooper and colleagues compiled a list of questions relating to study
sensitivity [23].
4. Separate assessments may have to be made for different outcomes. The risk of bias
will often differ across different outcomes. For example, bias in the ascertainment of death
from all causes is much less likely than for a subjective outcome, such as quality of life or pain,
or for an outcome that relies on clinical judgment, such as pneumonia.
5. Assessments should be documented. It is good practice to copy and archive the text
from the article on which an assessment regarding the risk of bias is based. Such
overestimated. Negative exposure controls are usefully introduced in questionnaires to
gauge possible recall bias in case-control studies. A study of the association between
multiple sclerosis (MS) and childhood infections included questions on other childhood
events not plausibly associated with MS, such as fractures and tonsillectomy [54].
Table 1. Signalling questions for different bias domains.
Bias domain Study design Signalling question
Confounding Any What are the important variables that might confound the effect of
the exposure?
Any Were these variables measured with precision and at appropriate
points in time?
Any Did the authors use an appropriate analysis method or design that
adjusted for all of the important confounding variables?
Selection bias Cohort studies/cross-
sectional studies
Was selection into the study unrelated to both the exposure and
outcomes?
Cohort studies/cross-
sectional studies
Were the reasons for missing data unrelated to the exposure and
outcomes?
Case-control studies Were the controls sampled from the population that gave rise to the
cases?
Case-control studies Were the reasons for missing data related to case or control status?
Information
bias
Cohort studies/cross-
sectional studies
Were outcome assessors unaware of the exposure status of study
participants?
Cohort studies/cross-
sectional studies
Were the methods of outcome assessment comparable across
exposure groups?
Case-control studies Was the definition of case status/control status applied without
knowledge of exposure status?
Case-control studies Was data collection on exposure status unaffected by knowledge of
the outcome or risk of the outcome?
https://doi.org/10.1371/journal.pmed.1002742.t001
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documentation increases transparency, facilitates discussion in case of disagreement, and
allows for replication of assessments.
6. Summary scores should be avoided. Summary scores involve weighting of bias
domains; typically, each item in a score is weighted equally (0 or 1 point), but the importance
of a bias will depend on the context, and one bias may be more important than another
[59,60]. The situation is made worse if the scale includes items that are not consistently related
to bias. For example, the Newcastle-Ottawa Scale includes quality items of questionable valid-
ity, such as comparable nonresponse among cases and controls [61]. Rather than calculating
summary scores, a conservative approach classifies the study at the level of risk of bias corre-
sponding to the highest risk identified for individual domains.
7. Thinking about a hypothetical, unbiased trial may be helpful. It may useful, as a
thought experiment, to think of a hypothetical RCT that would answer the review question
posed in the systematic review [56]. Such a trial will often be unfeasible and unethical, but the
thought experiment may help to sharpen the review question and clarify the potential biases in
the observational studies. S3 Box gives an example.
Reporting biases, P hacking, and analytic choices
An important source of bias that may undermine conclusions from any systematic review or
meta-analysis is the selective publication of studies. It is known that studies with ‘positive’
results (i.e., statistically significant effects) are more likely to be published than negative stud-
ies, introducing a distorted overall picture of an association. There is robust evidence of publi-
cation bias and other reporting biases for RCTs [62,63]: positive trials are more likely to be
published, to be published quickly, to be published more than once, and to be cited, making it
more likely that they will be included in systematic reviews.
Selective publication of results may also be a problem within studies, when many different
exposures and outcomes were examined. If only the statistically significant associations are
fully analysed, written up, and published, the results of systematic reviews will be distorted. A
related issue arises when the selection of the study population or statistical model is chosen
based on the P value (‘P hacking’) [64].
How to deal with risk of bias?
Results from the risk of bias analysis should be presented in a transparent way, tabulating risk
of bias elements for each included study. An important consideration is how to deal with stud-
ies at high risk of bias. If the aim is to present the best available evidence on the efficacy of a
medical intervention, the review is often restricted to studies at low risk of bias. For systematic
reviews of observational studies of etiology, we generally advise against excluding studies
based on risk of bias assessments. Including all studies and exploring the impact of the risk of
different biases and of study sensitivity on the results in stratified or regression analyses will
often provide additional insights, as discussed below.
Exploring and exploiting heterogeneity
The studies included in a systematic review will generally vary with respect to design, study
populations, and risk of bias [1]. Mapping of heterogeneity between studies [65] may not only
provide a useful overview but also help decide whether or not to combine studies statistically
in a meta-analysis. Such diversity may provide opportunities for additional insights and can
explicitly be exploited [66]. For example, the association of Mycobacterium avium subspecies
paratuberculosis (MAP) with Crohn disease was examined in a review of case-control studies
that compared cases of Crohn disease with controls free of inflammatory bowel disease or with
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ulcerative colitis patients [67]. The association was strong for both comparisons, indicating
that the association with MAP is specific to Crohn disease and not a general (epi)phenomenon
in inflammatory bowel disease (see also Box 4 on negative controls).
Diversity in study settings also may provide insights. Lifestyle factors such as smoking,
physical activity, sexual behaviour, or diet are exposures of interest in many observational
studies, but they are highly correlated in Western societies. Their independent effects, for
example, on cancer risk, are therefore difficult to disentangle. The inclusion of studies in spe-
cial populations, for example, defined by religion or geographical regions with different life-
style patterns, may therefore help understand (residual) confounding. Similarly, studies that
measured exposures and confounding factors more or less precisely, used different methods to
adjust for confounding variables (Box 4), or were generally at higher or lower risk of bias will
be valuable in this context. For example, a meta-analysis showed that the relationship between
induced abortion and breast cancer was evident in case-control studies but not in cohort stud-
ies [68]: the association observed in case-control studies was probably due to recall bias.
The thoughtful exploitation of sources of heterogeneity at the design stage or exploration in
the analysis are therefore an important part of systematic reviews and meta-analyses of obser-
vational studies of etiology. Analyses should either be prespecified in the study protocol or
interpreted in the spirit of exploratory data analyses. Exploration of heterogeneity starts with
the visual inspection of forest plots and funnel plots. Statistical techniques include subgroup
analyses and metaregression, as discussed below.
Meta-analysis: To pool or not to pool?
After careful examination of risk of bias and other sources of heterogeneity, reviewers must
consider whether statistically combining effect estimates is appropriate for all studies, for a
subgroup of studies, or not appropriate at all. Authors provide different reasons for not pool-
ing data [69], and different opinions exist on how to approach this question [18]. Consider-
ations for or against pooling should be based on judgments regarding study diversity,
sensitivity, and risk of bias rather than solely on statistical measures of heterogeneity (see
below) for two reasons. First, in the absence of statistical heterogeneity, combining results
from biased studies will produce equally biased combined estimates with narrow confidence
intervals that may wrongly be interpreted as definitive evidence. The inclusion of studies at
high risk of bias will often, but not always, introduce heterogeneity. For example, the protective
effect of a diet rich in beta-carotene on cardiovascular mortality shown in observational studies
was very consistent across studies. However, randomised trials of beta-carotene supplementa-
tion did not show any benefit, making it likely that the results of observational studies were
confounded to a similar extent by other aspects of a healthy diet and lifestyle [41]. Second,
even in the presence of statistical heterogeneity, combining studies may be appropriate if stud-
ies are at low risk of bias and results are qualitatively consistent, indicating some degree of ben-
efit or risk. If authors decide not to provide one overall pooled estimate, stratified meta-
analyses (by study design or population) may be considered. Be mindful that a systematic
review that documents heterogeneity and risk of bias will still provide a valuable contribution
even without a formal meta-analysis.
Statistical analysis
Fixed- versus random-effect models in the context of observational studies
Once the decision has been made that (some) studies can be combined in a meta-analysis,
reviewers need to decide whether to use a fixed-effect or a random-effects model or both.
These models have been described extensively [70]. In short, fixed-effect analyses assume that
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all studies estimate the same underlying effect and that differences between effect estimates are
due to sampling variation. In contrast, random-effects models assume that underlying true
effects vary between studies. In the presence of statistical heterogeneity, effect estimates will
differ because smaller studies receive more weight in the random-effects than in the fixed-
effect model, and the random-effects confidence interval will be wider because it additionally
incorporates the between-study variation. In the absence of statistical heterogeneity, results
from random- and fixed-effect models will be identical.
In observational studies, population characteristics and exposure or outcome definitions
will likely differ across studies. The assumption that all these studies estimate the same under-
lying effect is rarely justified, and using a random-effects model for combining observational
studies therefore seems reasonable [18]. An important consideration in this context is the
question of whether, for a given research question, smaller or larger studies are at greater risk
of bias. In clinical research, large multicentre trials tend to be at lower risk of bias than small
single-centre studies, supporting the use of fixed-effect models. The opposite may be the case
in observational etiological research, for which smaller studies may have collected better data
on exposures and confounders. The model to be used should be specified in advance, but pre-
senting results from both models in a sensitivity analysis may be informative. Of note,
although random-effects models allow for between-study heterogeneity, they do not help to
understand the sources of heterogeneity [71].
Statistical measures of between study heterogeneity
Methods to assess statistical heterogeneity include the I2 statistics and Cochrane’s Q test for
heterogeneity. The Q test assesses whether variation between effect estimates is likely due to
chance alone; the I2 statistic quantifies the amount of variation between studies that cannot
be attributed to chance [72]. These measures should be interpreted with caution: the I2 sta-
tistic is captured with uncertainty [73], and Cochrane’s Q test has limited power to detect
heterogeneity when the number of included studies is low [74]. Since the number of studies
included in a review of observational studies is typically 10 to 20 [1], statistical power will
generally be low. Moreover, the statistical verdict on presence or absence of heterogeneity
does not need to coincide with the reviewers’ judgment on presence or absence of study
diversity or risk of bias. It might be that important study diversity does not translate into
statistical heterogeneity.
Funnel plot (a)symmetry
A funnel plot is a graphical tool to investigate whether estimates from smaller studies differ
from those of larger studies. Effect sizes are plotted against the standard error or precision of
the estimate (which relate to study size) [75]. If estimates from different studies differ only
because of random variation, then they will scatter symmetrically around a central value, with
variation decreasing as precision increases. The plot will thus resemble an inverted funnel.
Asymmetry of the funnel plot means that there is an association between study size and effect
estimates or a ‘small study effect’ [76], with smaller studies typically showing larger effects.
This may be due to several reasons, including true heterogeneity (i.e., smaller studies differ
from larger ones in terms of study population, exposure levels, etc.), selection bias (i.e., the
selective publication of small studies showing an effect), bias in design or analysis, or chance
[77,78]. Asymmetry should not be equated with publication bias. Particularly in the context of
observational studies, there are many other sources of heterogeneity and funnel plot
asymmetry.
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Metaregression
Metaregression is used to investigate whether study characteristics are associated with the
magnitude of effects and whether specific study characteristics can explain (some of) the
observed statistical heterogeneity. The presence of heterogeneity motivates metaregression
analyses, and random-effects metaregression should therefore always be used. The use of
fixed-effect metaregression is conceptually nonsensical and yields a high rate of false-positive
results [79].
Variables included in a metaregression model may be study features, such as study design,
year of publication, or risk of bias; or characteristics of the people included in the different
studies, such as age, sex, or disease stage. These variables are potential effect modifiers. For
example, the risks of smoking decrease with advanced age. Only a few variables should be
included in a metaregression analysis (about one variable per 10 studies), and they should be
prespecified to minimise the risk of false-positive results [80]. In multivariable metaregression,
the model presents mutually adjusted estimates, and permutation tests to adjust for multiple
testing can be considered [80]. When including characteristics of study participants, note that
associations observed at the study level may not reflect those at the individual level—the so-
called ecological fallacy [81]. This phenomenon is illustrated in Fig 3 for trends in the CD4
positive lymphocyte count in HIV-positive patients starting antiretroviral therapy (ART): in
five of the six studies, the CD4 cell count at the start of ART increased over time, which was
not shown in metaregression analysis at the study level. A graphical display of the metaregres-
sion is informative [82]. Such a graph shows for each study the outcome (e.g., a relative risk or
a risk difference) on the y-axis, the explanatory variable on the x-axis, and the regression line
that shows the association between two variables. In a metaregression graph, the weight of the
studies is preferably shown by ‘bubbles’ around the effect estimates, with larger bubbles relat-
ing to studies with more weight in the analysis (Fig 3 provides a schematic example).
Combining different metrics
Meta-analyses depend on how data are presented in individual articles. Especially in the con-
text of observational studies, researchers may face the problem that different metrics are used
for the same exposure–outcome association, depending on study design or statistical models
used. Consider the association between smoking (exposure) and blood pressure (outcome). In
cohort studies, hazard ratios, incidence rate ratios, risk ratios, or odds ratios can be estimated
Fig 3. Illustration of the ecological fallacy. Hypothetical example of aggregate and individual level CD4 cell count
data at the start of ART. Adapted from [83]. ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1002742.g003
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when the outcome is dichotomized, whereas mean difference or standardised mean difference
may be reported if this is not the case.
How can different metrics be combined in meta-analysis? There are two issues to consider,
one conceptual, one more technical. When studies report different ratio metrics, for example,
hazard ratios, risk ratios, or odds ratios, they may be combined ignoring the differences in
metrics. This may be appropriate depending on which study designs were included (cohort
studies or case-control studies) and how participants were sampled in case-control studies
[84,85]. As a general rule, the different ratio metrics can be combined if the outcome under
study is rare (<5%), which is often the case in etiologic studies. If the outcome is not rare,
researchers must be more careful because the odds ratio will substantially overestimate the rel-
ative risk. This property of the odds ratio is a reflection of the fact that for non-rare outcomes,
the odds is larger than the risk (for example, if the risk is 0.8, the corresponding odds is 4).
It is also possible to combine relative risks with other metrics like standardised mean differ-
ences or correlation coefficients. This requires transformation from an odds ratio in a stan-
dardised mean difference (or vice versa) [86] or an odds ratio in a correlation coefficient
[87,88]. For example, in a meta-analysis of the association between fibrinogen levels on post-
operative blood loss, studies reported odds ratios, regression coefficients, correlation coeffi-
cients, and/or P values [89]. All effect measures were transformed into correlation coefficients
and subsequently combined in a meta-analysis [89].
Dose-response meta-analysis
In many epidemiologic studies, several levels of exposure are compared. For example, the
effect of blood glucose on cardiovascular outcomes can be studied across several groups of glu-
cose levels, using one category as reference. However, different studies may report different
categories of the exposure variable (tertiles, quartiles, or quintiles). One approach is to meta-
analyse the estimates by comparing the lowest and highest category. This is not recommended
because the meaning of lowest versus highest differs across studies. A more sophisticated
approach is to model the association between the exposure and outcome to estimate the
increase (or decrease) in risk associated with one unit (or other meaningful incremental)
increase in exposure. See references for technical details [90,91]. For example, a meta-analysis
of the association between Homeostasis Model Assessment Insulin Resistance (HOMA-IR)
and cardiovascular events used dose-response modelling to estimate that the cardiovascular
risk increased by 46% per one standard deviation increase in HOMA-IR [24].
Interpretation and discussion of results
Reviewers should discuss their results in a balanced way: many of the included studies might
be far from perfect, even if the overall estimate comes with a narrow confidence interval [41],
and researchers should keep in mind that statistical significance is not an indicator of whether
a true relation exists or not. Big numbers cannot compensate for bias. If included studies have
a low risk of bias and heterogeneity does not seem large, researchers may conclude that the
main results provide reasonably valid estimates. On the other hand, if many studies are at high
risk of bias, researchers should conclude that the true effect remains uncertain. The Grades of
Recommendation, Assessment, Development, and Evaluation (GRADE) system can be helpful
to formally judge ‘the extent of our confidence that the estimates of an effect are adequate to
support a particular decision or recommendation’ [92], taking into account study design, risk
of bias, degree of inconsistency, imprecision and indirectness (applicability) of results, and
reporting bias [93].
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One or a few studies might suffice to demonstrate that a relevant bias likely exists and that
all other studies suffer from it. For example, many cohort studies have shown that higher C-
reactive protein (CRP) levels are associated with cardiovascular risk. However, other cardio-
vascular risk factors, including smoking, obesity, and physical activity, are associated with
higher CRP levels, and these may confound the association with cardiovascular disease levels
[94]. No association was seen in mendelian randomisation studies [94], which used genetic
variants that are related to CRP levels but independent of the behavioural or environmental
risk factors that confound the association in epidemiological studies [95] (see Box 1). Mende-
lian randomisation studies and classic cohort studies in fact estimate different ‘effects’: lifelong
exposure in mendelian randomisation versus exposure from a certain (often not well-defined)
time-point onward. It should be noted that when mendelian randomisation studies include
participants later in life, selection bias may occur [96]. Evidence from mendelian randomisa-
tion studies, if available, should always be taken into account when interpreting the results
from systematic reviews of epidemiological studies. A useful guide for reading mendelian ran-
domisation studies has recently been published [97].
When assessing causality, integration of different sources of evidence (e.g., ecological stud-
ies, basic research on mechanisms) may facilitate a final judgement; trying to obtain an inte-
grated verdict based on results from different analytic or epidemiologic design approaches, for
which each approach has different and preferably unrelated sources of potential bias, is called
triangulation [98]. If different approaches all point to the same conclusion, this strengthens
confidence that the finding may be causal [98]. For example, in the discussion on smoking and
lung cancer, time trends in lung cancer were an important argument against the hypothesis
that an inherited trait would cause lung cancer as well as smoking [99]. Discussing competing
explanations systematically will add value to the interpretation of the results [100]. Especially
in the field of toxicology, mechanistic evidence plays an important role in causal inference,
and systematic review of this literature is encouraged [17]. Clearly, understanding pathways
requires more than quickly searching for a few articles that support the hypothesis (’cherry
picking’) [17]. Systematic reviews on insulin-like growth factor or adiposity and cancer risk
took laboratory, animal, and human evidence into account to judge the plausibility of different
mechanisms [40,101].
Finally, the importance of the results in terms of clinical and public health relevance should
be discussed. The identification of likely causes does not necessarily translate into recommen-
dations for interventions [102]. For example, based on epidemiological and other evidence,
obesity probably increases the risk of several cancers [101,103], but this does not mean that los-
ing weight will reduce cancer risk. Obesity may have exerted its detrimental effect, and differ-
ent interventions to reduce obesity have different effects on cancer risk [104].
An important strength of systematic reviews is that they generate a clear overview of the
field and identify the gaps in the evidence base and the type of further research needed. The
usual statement that ’more research is needed’ can thus be replaced by detailed recommenda-
tions of specific studies. Furthermore, having assessed the strengths and limitations of many
studies, reviewers will be in an excellent position to name the pitfalls that need to be avoided
when thinking about future research.
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